
    
      This study will be conducted in 3 phases: a Prerandomization Phase, a Randomization Phase,
      and an Extension Phase. The Extension Phase will consist of the Optional Open Label (OOL)
      Lenvatinib Treatment Period and the Follow-up Period.
    
  